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‘‘Homage  to  thee,  O  my  heart!  Homage  to  you,  O my
kidneys!’’
The  Egyptian  Book  of  the Deada
Many  centuries  ago,  traditional  Chinese  medicine  --
today,  quite  rightly,  a subject  of  some controversy  in the  Por-
tuguese  medical  community  --  described  a  disorder  termed
‘‘heart  and  kidney  failing  to  link,’’  suggesting  a  close  con-
nection  between  dysfunction  of  the  kidneys  and  of  the heart.
These  may  have  been  the  first  references  to what  is now
known  as  cardiorenal  syndrome  (CRS),  a complex  ‘‘disorder
of  the  heart  and  the  kidneys  whereby  acute  or  chronic
dysfunction  in one  organ may  induce  acute  or  chronic  dys-
function  of  the other’’.1--3
Five  subtypes  of  CRS  are  now  recognized,  but  in
all  of  them,  both  organs  (heart  and kidneys)  show  or
develop  structural  and/or  functional  alterations.4,5 Type
1  (acute  CRS)  --  the subject  of  this  editorial  --  refers  to  acute
worsening  of  heart  function  leading  to  acute  kidney  injury
(AKI)  and/or  dysfunction,1--3 and  can  be  found  in 19-45%
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of  patients  with  acute  decompensated  heart  failure  (ADHF)
presenting  with  AKI.4 AKI  mostly  occurs  early,  within  3-5 days
of  hospitalization,  and  appears  to  be  a predictor  of  even
worse  prognosis,  associated  with  higher  short-  and  long-term
all-cause  and  cardiovascular  mortality  and  prolonged  hospi-
talization.  The  well-documented  risk  factors  for AKI  in the
context of  AHF  are  a  history  of  diabetes,  severity  of  car-
diac  dysfunction  on  admission,  use  of  high-dose  diuretics
(particularly  loop  diuretics,  but  also  thiazides),  vasodilator
therapy,  and  use  of  larger radiocontrast  volumes.4
The  clinical  presentation  of  type 1 CRS usually  includes
rapid  worsening  renal  function  (WRF)  (suggestive  of altered
renal  perfusion,  unless  proven  otherwise),  resulting  in  vol-
ume  overload  with  signs and symptoms  of  fluid retention,
pulmonary  rales  and  systemic  congestion,  less frequently  in
low  cardiac  output  with  peripheral  hypoperfusion,  and  in
poor  response  to  diuretics.2,4,5 It  should  be borne  in mind
that in  the context  of  AHF  diuretic  resistance  is  multifacto-
rial  and includes,  in  varying  degrees,  impaired  renal  blood
flow,  altered  drug  reabsorption,  reduced  glomerular  filtra-
tion,  low albumin  concentrations,  and  increased  levels  of
urea  nitrogen  and other  organic  acids  competitively  imped-
ing  diuretic  availability  at  the  site of  action.6,7 Ideally,  in
order  to  recognize  renal  dysfunction  and  to stratify  the
severity  of  AKI,  the risk,  injury,  failure,  loss  of kidney  func-
tion,  and end-stage  kidney  disease  (RIFLE)  and  Acute  Kidney
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Injury  Network  (AKIN)  classifications  should  be  applied.  The
former  is  based  on  changes  in serum  creatinine  (SCr)  or
glomerular  filtration  rate  (GFR) and/or  urine  output,  and is
a  good  predictor  of AKI  severity  and  outcome.  The  AKIN  clas-
sification  is  a  modified  adaptation  of RIFLE, and can  increase
the  sensitivity  and specificity  of  AKI  diagnosis.  Although  clin-
ically  available  biomarkers  are  sometimes  inadequate  for  a
diagnosis  of  CRS  and  detection  of AKI  in ADHF,  in clinical
practice  the  suspicion  of  type  1  CRS derives  from  an increase
in  SCr  and  blood  urea  nitrogen  (BUN).
BUN  is a serum  by-product  of  protein  metabolism  and
is  probably  one  of  the oldest  short- as  well  as  long-
term  prognostic  markers  in patients  with  heart  failure.
In  the  Acute  Decompensated  Heart  Failure  National  Reg-
istry  (ADHERE)  database,  BUN  ≥43  mg/dl was  the single
best  predictor,  followed  by  systolic  blood  pressure  <115
mmHg  on  admission  and  SCr  ≥2.75  mg/dl (243.1  mol/l),  of
in-hospital  mortality  among  65  275  AHF  admissions.  These
findings  have  been  replicated  in other  studies  and  BUN
levels  should  be  measured  in routine  prognostic  assess-
ment  of  ADHF.8 Creatinine  is  a  breakdown  product  of
creatine  phosphate  in  muscle  tissue,  and  increases  in the
blood  when  GFR decreases,  an  indication  of  renal  dys-
function.  Increases  in SCr  elevations  are also  associated
with  worse  outcomes  in  heart  failure  patients,  and  are a
strong  independent  predictor  of  both  one-  and  five-year
mortality.8
However,  as  Martins  et  al.9 note in  this issue  of the  Jour-
nal,  an  increase  of  SCr  in  AHF  patients  does  not  always
imply  renal  dysfunction  or  worse  prognosis.  As  the  authors
point  out,  AHF  patients  with  mild  creatinine  elevation  but
without  established  renal  failure  have  a  better  prognosis,
since  these  changes  are  due  to  hemoconcentration  (HC)
rather  than  to  true  WRF.  It  should  be  noted that  in  this
case,  HC  arises  from  an absolute  or  relative  loss  of water
from  blood  plasma  (deshydremia).  In Martins  et  al.’s  paper,
HC  was  defined  as  an  increase  in hemoglobin  during hospi-
tal  stay,  estimated  by  subtracting  hemoglobin  at  discharge
from  hemoglobin  at  admission;  a similar  definition  has  been
used  by  other  investigators.10--14 In  their  study,  as  in oth-
ers,  HC  was  associated  with  a better  prognosis  in patients
with  or  without  WRF,  acting  as  a surrogate  for  anticongestive
therapy,  and  had  prognostic  value in AHF  patients  without
CKD  but  with  elevated  SCr.  It would  therefore  be a  mis-
take  to  argue  that  a simple  increase  in  SCr  indicates  AKI,
and  in  fact  when  associated  with  HC3 --  with  no renal  fail-
ure  or  chronic  kidney  disease  --  it  is  associated  with  better
prognosis  and  survival.  Such  cases should  be  reclassified  as
‘pseudo-WRF’.
On  the  whole,  the article  by  Martins  et  al. is  clear,  cred-
ible  and  well  researched,  with  an accurate  and  judicious
description  of  its  limitations:  its  single-center  and  retro-
spective  nature,  the  importance  of  missing  data  such  as  SCr
and  left  ventricular  ejection  fraction,  and  the fact that  phar-
macological  therapy  at discharge  was  not  recorded  (with
possible  effects  on  prognosis).
Diuretics  (mainly,  but  not  only, loop  diuretics)  are  the
cornerstone  of  ADHF  and  CRS treatment.  They  relieve
renal  venous  congestion  and  fluid  overload  and improve
patients’  symptoms  and comfort,  and  their  early  use  in
severe  ADHF  can  reduce  mortality.5,6 However,  they  are
a  double-edged  sword:  they  may  worsen  kidney  function
and  trigger  even  more  neurohormonal  systems.  The  use
and  effects  of diuretic  therapy  must  therefore  be care-
fully  monitored.5,6 HC  may  be linked  with  increased  risk  of
WRF  during hospitalization,  increased  diuretic  doses,  and
greater  weight  loss.15 However,  in multivariate  analysis,  HC
is  not linked with  mortality,  and  an  early  increase  (in  the
first  week)  in hemoglobin  is  independently  associated  with
a  favorable  outcome,  despite  a  slight  worsening  of  renal
function.16
Future  research  needs  to  focus  on  the differences
between  and determinants  of  late  and  early  HC  in AHF  and
to  determine  the  cutoffs  between  them  --  because,  appar-
ently,  only  late  HC  is  associated  with  improved  survival10 --
and,  bearing  in  mind  that  HC  can be a surrogate  for  suc-
cessful  decongestion  in AHF,  to clarify  why in some  patients
there  is  a conflict  between  HC  and  clinical  assessment  of
venous  congestion,  with  persistent  congestion  at discharge
linked  with  increased  mortality  that  is  not  HC-dependent.
Finally,  as  Martins  et al. suggest,  HC  is  associated  with
better  outcomes  but cannot  replace  clinical  assessment  in
the  initial  diagnosis  of  AHF  and  a proper  diagnostic  workup
that  includes  specific  biomarkers,  as  well  as  BUN,  SCr,
hemoglobin  and hematocrit.  In  the  meantime,  all  patients
with  AHF  should  promptly  start  pharmacological  and  non-
pharmacological  treatment  in parallel,  as  recommended  in
the  most recent  guidelines.5,6
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